<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Cetuximab-containing chemotherapy is known to be effective for KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>; however, it is not clear whether cetuximab-based preoperative <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> confers an additional benefit compared with <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> without cetuximab in patients with locally advanced <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND MATERIALS: We analyzed EGFR, KRAS, BRAF, and PIK3CA mutation status with direct sequencing and epidermal growth factor receptor (EGFR) and Phosphatase and tensin homolog (PTEN) expression status with immunohistochemistry in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples of 82 patients with locally advanced <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> who were enrolled in the IRIX trial (preoperative <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> with irinotecan and <z:chebi fb="0" ids="31348">capecitabine</z:chebi>; n=44) or the ERBIRIX trial (preoperative <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> with irinotecan and <z:chebi fb="0" ids="31348">capecitabine</z:chebi> plus cetuximab; n=38) </plain></SENT>
<SENT sid="2" pm="."><plain>Both trials were similarly designed except for the administration of cetuximab; radiation therapy was administered at a dose of 50.4 Gy/28 fractions and irinotecan and <z:chebi fb="0" ids="31348">capecitabine</z:chebi> were given at doses of 40 mg/m2 weekly and 1650 mg/m2/day, respectively, for 5 days per week </plain></SENT>
<SENT sid="3" pm="."><plain>In the ERBIRIX trial, cetuximab was additionally given with a loading dose of 400 mg/m2 on 1 week before radiation, and 250 mg/m2 weekly thereafter </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Baseline characteristics before <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> were similar between the 2 trial cohorts </plain></SENT>
<SENT sid="5" pm="."><plain>A KRAS mutation in codon 12, 13, and 61 was noted in 15 (34%) patients in the IRIX cohort and 5 (13%) in the ERBIRIX cohort (P=.028) </plain></SENT>
<SENT sid="6" pm="."><plain>Among 62 KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients, major pathologic response rate, disease-free survival and pathologic stage did not differ significantly between the 2 cohorts </plain></SENT>
<SENT sid="7" pm="."><plain>No mutations were detected in BRAF exon 11 and 15, PIK3CA exon 9 and 20, or EGFR exon 18-24 in any of the 82 patients, and PTEN and EGFR expression were not predictive of clinical outcome </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: In patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> locally advanced <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e>, the addition of cetuximab to the <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> with irinotecan plus <z:chebi fb="0" ids="31348">capecitabine</z:chebi> regimen was not associated with improved clinical outcome compared with <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> without cetuximab </plain></SENT>
</text></document>